You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 27, 2024

Claims for Patent: 7,569,554

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,569,554

Title:	Synergistic treatment of cancer using immunomers in conjunction with therapeutic agents
Abstract:	The invention relates to the therapeutic use of immunostimulatory oligonucleotides and/or immunomers in combination with chemotherapeutic agents to provide a synergistic therapeutic effect.
Inventor(s):	Kandimalla; Ekambar R. (Southboro, MA), Agrawal; Sudhir (Shrewsbury, MA), Wang; Daqing (Bedford, MA), Bhagat; Lakshmi (Framingham, MA), Yu; Dong (Westboro, MA)
Assignee:	Idera Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:	10/846,167
Patent Claims:	1. A method for treating cancer comprising administering to a patient an immunomer in combination with a monoclonal antibody selected from Panorex.RTM. (edrecolomab), Rituxan.RTM. (rituximab), Mylotarg.RTM. (gemtuzumab ozogamicin), Campath.RTM. (alemtuzumab), Zevalin.RTM. (ibritumomab tiuxetan), Bexxar.RTM. (tositumomab), Erbitux.RTM. (cetuximab), Avastin.RTM. (bevacizumab or Herceptin.RTM. (trastuzumab), wherein the immunomer comprises the structure 5'-TCGTTGX-Y-XGTTGCT-5' wherein X is a C3 linker and Y is a glycerol linker or comprises the structure (SEQ ID NO 18): TABLE-US-00017 ##STR00080## ##STR00081## ##STR00082## and wherein the anti-tumor effects of the monoclonal antibody are enhanced when administered in combination with the immunomer. 2. A pharmaceutical formulation comprising an immunomer, wherein the immunomer comprises the structure 5 '-TCGTTGX-Y-XGTTGCT-5' wherein X is a C3 linker and Y is a glycerol linker or comprises the structure (SEQ ID NO 18): TABLE-US-00018 ##STR00083## ##STR00084## ##STR00085## a monoclonal antibody selected from Panorex.RTM. (edrecolomab), Rituxan.RTM. (rituximab), Mylotarg.RTM. (gemtuzumab ozogamicin), Campath.RTM. (alemtuzumab), Zevalin.RTM. (ibritumomab tiuxetan), Bexxar.RTM. (tositumomab), Erbitux.RTM. (cetuximab), Avastin.RTM. bevacizumab or Herceptin.RTM. (trastuzumab) and a physiologically acceptable carrier.

Details for Patent 7,569,554

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997	⤷ Try a Trial	2023-05-16
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002	⤷ Try a Trial	2023-05-16
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998	⤷ Try a Trial	2023-05-16
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017	⤷ Try a Trial	2023-05-16
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	05/07/2001	⤷ Try a Trial	2023-05-16
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	11/14/2014	⤷ Try a Trial	2023-05-16
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.